XERIS PHARMACEUTICALS INC's ticker is and the CUSIP is 98422LAA5. A total of 6 filers reported holding XERIS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,212 | -10.4% | 11,500,000 | 0.0% | 0.02% | 0.0% |
Q2 2023 | $12,519 | +32.6% | 11,500,000 | +9.5% | 0.02% | +25.0% |
Q1 2023 | $9,439 | +8.9% | 10,500,000 | 0.0% | 0.01% | 0.0% |
Q4 2022 | $8,668 | -99.9% | 10,500,000 | 0.0% | 0.01% | -14.3% |
Q3 2022 | $9,802,000 | +2.9% | 10,500,000 | 0.0% | 0.01% | +7.7% |
Q2 2022 | $9,526,000 | -21.4% | 10,500,000 | 0.0% | 0.01% | -7.1% |
Q1 2022 | $12,123,000 | -6.8% | 10,500,000 | 0.0% | 0.01% | 0.0% |
Q4 2021 | $13,013,000 | +4.6% | 10,500,000 | 0.0% | 0.01% | 0.0% |
Q3 2021 | $12,446,000 | -20.7% | 10,500,000 | +5.0% | 0.01% | -22.2% |
Q2 2021 | $15,687,000 | -12.9% | 10,000,000 | -5.9% | 0.02% | -18.2% |
Q1 2021 | $18,010,000 | +30.2% | 10,625,000 | +34.9% | 0.02% | +29.4% |
Q4 2020 | $13,836,000 | +78.2% | 7,875,000 | +96.9% | 0.02% | +54.5% |
Q3 2020 | $7,763,000 | +124.0% | 4,000,000 | +14.3% | 0.01% | +120.0% |
Q2 2020 | $3,466,000 | – | 3,500,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Context Partners Fund, L.P. | 3,240,000 | $6,256,000 | 1.36% |
Context Capital Management, LLC | 3,240,000 | $6,256,000 | 1.36% |
Sessa Capital IM, L.P. | 7,450,000 | $14,444,000 | 1.18% |
683 Capital Management, LLC | 7,500,000 | $14,550,000 | 1.07% |
SILVERBACK ASSET MANAGEMENT LLC | 2,500,000 | $4,850,000 | 1.02% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 18,000,000 | $36,116,000 | 0.88% |
CAMDEN ASSET MANAGEMENT L P /CA | 14,000,000 | $27,032,000 | 0.86% |
Soros Fund Management | 6,986,000 | $13,597,000 | 0.33% |
Hudson Bay Capital Management LP | 8,200,000 | $16,003,000 | 0.24% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 2,000,000 | $3,861,000,000 | 0.10% |